Search

Your search keyword '"Singeap, Ana Maria"' showing total 57 results

Search Constraints

Start Over You searched for: Author "Singeap, Ana Maria" Remove constraint Author: "Singeap, Ana Maria" Database Unpaywall Remove constraint Database: Unpaywall
57 results on '"Singeap, Ana Maria"'

Search Results

3. The Impact of Alcohol Consumption Pattern on Liver Fibrosis in Asymptomatic Patients

6. Impaired Intestinal Permeability Assessed by Confocal Laser Endomicroscopy—A New Potential Therapeutic Target in Inflammatory Bowel Disease

7. Changes in Components of Metabolic Syndrome after Antiviral Eradication in Hepatitis C Virus Infection

8. High prevalence of liver fibrosis among general population: a Romanian population-based study

9. Predictive Factors for the Prognosis of Alcoholic Liver Cirrhosis

10. Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter

11. Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter

12. Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals

13. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response

14. The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students

16. The Risk of Clostridioides difficile Infection in Cirrhotic Patients Receiving Norfloxacin for Secondary Prophylaxis of Spontaneous Bacterial Peritonitis—A Real Life Cohort

17. Long-term Risk of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C Virus Infection

18. Risk Factors for Extraintestinal Manifestations in Inflammatory Bowel Diseases - Data from the Romanian National Registry

20. 659 CT EVALUATION OF SKELETAL MUSCLE MASS DYNAMICS FOLLOWING SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HCV-RELATED COMPENSATED CIRRHOSIS TREATED WITH DIRECT ACTING ANTIVIRALS

21. Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

24. The Impact of the COVID-19 Pandemic on Gastrointestinal Endoscopy Activity in a Tertiary Care Center from Northeastern Romania

25. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter

26. Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications

28. Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease

29. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship

30. The Prevalence of HCV Infection and Risk Factors in a Hospital- Based Population Screening, a First Step to the Micro-Elimination of HCV Infection in Medical Institutions from Romania - Results of the HepC ALERT Study

33. Microelimination of chronic hepatitis C in Romania - another pathway to achieve national elimination goals by HepC ALERT project

35. Liver Remodeling on CT Examination in Patients with HCV Compensated Cirrhosis Who Achieved Sustained Virological Response after Direct-Acting Antivirals Treatment

39. Diagnosis and Treatment of Colonic Diverticular Disease: Position Paper of the Romanian Society of Gastroenterology and Hepatology

40. Sa1442 - Relative Adrenal Insufficiency in the Setting of Acute on Chronic Liver Failure – An Organ Dysfunction that Could Indicate Futility

43. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older

46. A Low Incidence of Hepatocellular Carcinoma in Patients with Genotype 1B Compensated Cirrhosis Treated with Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir  ± Ribavirin in a Tertiary Center: A Matter of Better Selection?

47. Efficacy and Safety of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir Plus/Minus Ribavirin for Treatment of HCV Genotype 1B Compensated Cirrhosis in Patients Aged 70 Years or Older

Catalog

Books, media, physical & digital resources